The last thing we want to do is jinx ourselves. But we are having a blast the past year with stock doubles. Since we are not traders, we really don’t see these stocks double in real-time. We don’t even have real-time quotes. The other thing is we rarely get involved with sub-dollar stocks to make 20-30% or even 100%.
So being up 100% isn’t a goal, it’s a sign (performance-wise) that things so far are going as planned. Before a stock can go up ten-fold (we’ve had 15 do that), they first have to go up two-fold.
Fairchild Gold (FAIR) up 100%
Zomedica (ZOMDF) up 143%
What usually happens with micro-caps like these, is we look up one day and say, “OMG it’s doubled.” Woo-hoo. What rarely happens is we click the sell button. Often to our later regret, but it is what it is.
Many of these stocks that doubled were highlighted after getting crushed (and/or reverse split), and most traded sideways for months and months after we highlighted them (not good fodder for traders). And then all of the sudden, they run – most likely fueled by traders – so a shout out to them.
Recent Doubles. From initiation to double, with some continuing considerably higher after doubling. Click on name for original post.
Allarity (ALLR) $0.70 to $2.05 – 6 months to double.
Ardelyx (ARDX) $1.57 to $9.74 – 14 months to double.
ATAI (ATAI) $1.80 to $4.89 – 26 months to double.
Brixton Metals (BBBXF) $0.05 to $0.10 – 2 days to double.
Cardiol Therapeutics (CRDL) $0.55 to $2.86 – 4 months to double.
Compass Pathways (CMPS) $2.36 to $5.17 – 4 months to double.
Fairchild Gold (FAIR) $0.035 to $0.075 – 2 months to double.
Quantum Bio Pharma (QNTM) $4.10 to $35 – 2 months to double. Almost a ten bagger!
Zomedica (ZOMDF) $0.035 to $0.09 – 6 months to double.
Upcoming Doubles?
This is really a way to jinx ourselves. So with caution, we’ll add we don’t ‘think’ these stocks will double (or double again). We’ll instead say we’re pretty sure they ‘could’ double!
It’s an odd cast of characters, to say the least with Beverages, Biotechs, Precious Metals and Psychedelics represented.
Initiation Price | Current Price | Double Price
Alkaline Water Company (WTER) $0.0165 | $0.0165 | $0.34
ATAI (ATAI) $1.80 | $4.89 | $9.78
Compass Pathways (CMPS) $2.36 | $5.17 | $10.30
Fairchild Gold (FAIR) $0.035 | $0.07 | $0.14
Oncolytics Bio (ONCY) $1.02 | $1.30 | $2.60
Perpetua Resources (PPTA) $13.60 | $17.12 | $34.24
PharmaTher (PHRRF) $0.04 | $0.25 | $0.50
Society Pass (SOPA) $01.20 | $1.15 | $2.40
Vystar (VYST) $0.11 | $0.15 | $0.30
As a reminder, these are not price targets. As in the shares could go straight down from here, or double and go back down, or double and then then go 5X higher.
Let’s look at charts of our two latest doubles.
Fairchild Gold
We are currently awaiting data, from their Chief data scientist, as mining samples were recently sent off to be analyzed.
As we mentioned in an earlier report, they have assembled a dream team of experts (mining, data analytics, legal and financial). This includes world renowned geologist, Dr. Sergei Diakov who was instrumental in the Oyu Tolgoi discovery in Mongolia worth $10-$15 billion and Nuevo Chaquiro discovery in Colombia valued at $30-$40 billion.
If there is no gold or cooper to be found, so be it. But if there is, our bet is he and his team will find it!
In the meantime, from looking at the volume increase in front (or tandem) with a price increase department, sometime appears to be brewing.
Look below to see what we mean. When we first reported on Fairchild, volume typically averaged under 100,000 shares or a mere $5,000. On August it traded 1000 shares or $50 – yes, funny. Especially in the light of Oracle trading 64 million shares this morning, gaining $220 billion in value in the process! Which must be some kind of record.
But that’s of course a different game. God bless the Oracle options traders and the real estate brokers in Austin Texas, where Oracle’s HQ is located. That’s enough in a one day gain, to purchase 110,000 homes at $2 million each. We wouldn’t want to get in a bidding war for a house there.
We will be updating the progress they have made on a daily basis for the next week. We don’t mean to ‘pester’ subscribers, but our Fairchild is “about to move big-time” antenna is quivering wildly.
Here’s the thing, even with 1 million shares trading at $0.07, that’s still less than $100,000 worth of shares trading hands. Our technical guy says if it breaks over $0.095, the next target is $0.20.
And because it is so thinly traded it could get there in a hurry, on favorable news. So we’ll do our best to make this opportunity as transparent and obvious as possible. It’s what we do. No predictions – just reporting on what’s currently developing..
Zomedica
SHORT TERM CHART
We’ve been watching Zomedica (ZOMDF) from the sidelines (luckily) for years. It always seemed undervalued (apparently only to us).
Business had and continues to be ‘good.’ For example in the most recent quarter, they reported, “We are very pleased with the 14% growth attained in the second quarter as we posted record year-over-year revenue for the 18th straight quarter,” said Larry Heaton, Chief Executive Officer of Zomedica.
Revenue for the second quarter of 2025 grew by 14% to $7.0 million, compared to second quarter 2024 revenue, highlighted by 86% growth in their Diagnostics segment. So a near $30 million annual run rate.
Sadly the stock has also fallen for nearly 18 straight quarters. Apparently it’s still too small for institutional ownership, and too boring for retail. Despite that quandary there comes a point where enough is enough.
That point started when the share price dropped below $0.20 and they got a ‘delisting’ notice from NASDAQ. That sent ‘loyal’ shareholders scrambling. So the company put up a reverse split vote to shareholders and they voted NO.
Next thing you know they get delisted and the share price hits an air-pocket, and we come off the sidelines at an incredibly gross undervaluation under cash at $0.035. The end of enough is enough. It was enough of the battering.
That day there was cash of $76 million versus a market cap of $38 million. Today there is cash of $58 million versus a market cap of $88 million. Still cheap, but it was originally a ‘once in a decade’ trading idea and the trade opportunity now seems complete.
So Auf Wiedersehen. Officially a gain of 211% for the track record. Not bad for 6 months and 3 days.
Original Write-Up: We Have a Trading Idea! Zomedica (ZOMDF)
We’re out of time, off to a meeting. We’ll be back with more on Fairchild tomorrow.
Forward looking statements
This presentation includes certain forward-looking statements about future events and/or financial results which are forward
looking in nature and subject to risks and uncertainties. Forward-looking statements include without limitation, statements
regarding the company’s plans, goals or objectives and future completion of mine feasibility studies, mine development
programs, capital and operating costs, production, potential mineralization and reserves, exploration results and future planning and objectives of Fairchild. Forward-looking statements can generally be identified by forward-looking terminology such as “may,” “will,”, “expect,” “intend,” “estimate,” “anticipate,” “believe,” or “continues” or the negative thereof or variations thereon or similar terminology. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from expectations include risks associated with mining generally and pre-development stage projects in particular including but not limited to changes in general economic conditions, litigation, legislative, environmental and other judicial, regulatory, technological and operational difficulties, labor relations matters, foreign exchange costs & rates. Revelers Media an associated firm of Institutional Analyst and Institutional Gold Analyst to has been hired by the Company to build a news related website to disseminate news and SEDAR filings for a monthly retainer of two thousand and five hundred dollars a month. It will further negotiate for an equity stake in the company.
